Maturation inhibitors are a class of HIV antiretroviral agents currently in development. They act at the viral maturation step, which involves cleavage of the structural protein “Gag,” resulting in the development of an infective viral particle. These agents aim to stop viral maturation by inhibiting Gag cleavage. While not currently in clinical use, they represent a promising new therapeutic class for HIV infection.
Combination antiretroviral agents with distinct mechanisms have become the mainstay of therapy for HIV infection. A variety of drug classes are available for use, as discussed elsewhere in this text, targeting viral enzymes including reverse transcriptase (RT), protease (PR), and integrase (IN). All currently recommended antiretroviral regimens use a combination of the above classes to provide therapeutic effect (Panel on Antiretroviral Guidelines for Adults and Adolescents 2014; Gunthard et al. 2014). The rationale for a combination approach to...
KeywordsRitonavir Atazanavir Dimethylsuccinyl
- Baichwal V, Austin H, Brown B, et al. Anti-viral characteristics in vitro of a novel maturation inhibitor, MPC-9055. In: Conference on retroviruses and opportunistic infections, Montreal; 2009.Google Scholar
- Hwang C, Sevinsky H, Ravindran P, et al. Antiviral activity/safety of a second-generation HIV-1 maturation inhibitor. In: Conference on retroviruses and opportunistic infections, Seattle; 2015.Google Scholar
- McCallister S, Lalezari J, Richmond G, et al. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther. 2008;13:A10.Google Scholar
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, §What to Start. 2014.Google Scholar
- Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007;51(10):3574–81.PubMedCentralCrossRefPubMedGoogle Scholar
- Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1997.Google Scholar
- Zhou J, Chen CH, Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol. 2006;80(24):12095–101.PubMedCentralCrossRefPubMedGoogle Scholar